

**Table S2****Health associations for each of the taxa on the screening test**

Associated: These taxa have been found to be more abundant in people who have this condition.

Inversely Associated: These taxa are found to be less abundant in people who have this condition.

Taxon	Associated	Inversely Associated
<i>Akkermansia muciniphila</i>	Type II Diabetes [30]	Obesity [39,40], Ulcerative Colitis [33], Crohn's disease [33]
<i>Anaerotruncus colihominis</i>	Bloating [41]	Obesity [1,42]
<i>Bacteroides fragilis</i>	Flatulence [43], Diarrhea [44,45]	
<i>Butyrivibrio crossotus</i>		Obesity [46,47]
<i>Clostridium difficile</i>	Diarrhea [48-50]	
<i>Collinsella aerofaciens</i>		IBS [4,51,52]
<i>Desulfovibrio piger</i>	IBD [53]	
<i>Dialister invisus</i>		Crohn's Disease [3]
<i>Methanobrevibacter smithii</i>	Abdominal Tenderness [54], Constipation [55]	Obesity [20,56]
<i>Oxalobacter formigenes</i>		Kidney Stones [57,58]
<i>Ruminococcus albus</i>		Ulcerative Colitis [59]
<i>Salmonella enterica</i>	IBS [5], Diarrhea [34-38]	
<i>Streptococcus sanguinis</i>	Kawasaki disease [60]	
<i>Vibrio cholerae</i>	Diarrhea [61,62]	
<i>Alistipes</i>		Obesity [1], IBS [1]
<i>Barnesiella</i>		Obesity [1]
<i>Bifidobacterium</i>		Constipation [2], Crohn's Disease [3], IBS [4]
<i>Campylobacter</i>	IBS [5], Diarrhea [6,7]	
<i>Clostridium</i>	Diarrhea [8,9]	
<i>Escherichia/Shigella</i>	Crohn's Disease [10-12], IBS [5], Diarrhea [13-17]	
<i>Fusobacterium</i>	IBD [18]	
<i>Lactobacillus</i>	Obesity [19-21]	Obesity [20], Type II Diabetes [22,23], IBS [4,24], Diarrhea [25]
<i>Odoribacter</i>		Ulcerative Colitis [10], Crohn's Disease [10]
<i>Prevotella</i>		Ulcerative Colitis [26-28]
<i>Roseburia</i>		Type II Diabetes [29-31], Ulcerative Colitis [32], Crohn's Disease [27,28], IBD [10]
<i>Ruminococcus</i>	Ulcerative Colitis [33], Crohn's Disease [3,28,33]	
<i>Salmonella</i>	Diarrhea [34-38]	
<i>Veillonella</i>	IBS [24]	

## References

- 1 Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science*. 2016;352: 565–569. doi:10.1126/science.aad3369
- 2 Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. *Aliment Pharmacol Ther*. 2012;35: 828–838. doi:10.1111/j.1365-2036.2012.05007.x
- 3 Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut*. 2011;60: 631–637. doi:10.1136/gut.2010.223263
- 4 Malinen E. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. *World J Gastroenterol*. 2010; 16: 4532–9. doi:10.3748/wjg.v16.i36.4532
- 5 Spiller RC. Role of infection in irritable bowel syndrome. *J Gastroenterol*. 2007;42 Suppl 17: 41–47. doi:10.1007/s00535-006-1925-8
- 6 Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. *Campylobacter* spp. as a Foodborne Pathogen: A Review. *Front Microbio*. *Frontiers*; 2011;2: 200. doi:10.3389/fmicb.2011.00200
- 7 Dasti JI, Tareen AM, Lugert R, Zautner AE, Groß U. *Campylobacter jejuni* A brief overview on pathogenicity-associated factors and disease-mediating mechanisms. *International J of Medical Microbiology*. Elsevier; 2010;300: 205–211. doi:10.1016/j.ijmm.2009.07.002
- 8 Brynestad S, Granum PE. *Clostridium perfringens* and foodborne infections. *Int J Food Microbiol*. 2002;74: 195–202.
- 9 Lund BM, Peck MW. *Clostridium botulinum*. *Guide to Foodborne Pathogens*. Oxford: John Wiley & Sons; 2013. pp. 91–111. doi:10.1002/9781118684856.ch6
- 10 Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol*. *BioMed Central*; 2012;13: R79. doi:10.1186/gb-2012-13-9-r79
- 11 Kang S, Denman SE, Morrison M, Yu Z, Doré J, Leclerc M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis*. 2010;16: 2034–2042. doi:10.1002/ibd.21319
- 12 Thorkildsen LT, Nwosu FC, Avershina E, Ricanek P, Perminow G, Brackmann S, et al. Dominant Fecal Microbiota in Newly Diagnosed Untreated Inflammatory Bowel Disease Patients. *Gastroenterology Research and Practice*. 2013;2013: 1–13. doi:10.1155/2013/636785
- 13 Liu D. Chapter 64. Diarrhoeagenic *Escherichia coli*. *Molecular Medical Microbiology, Three-Volume Set*. Elsevier Ltd; 2014. pp. 1133–1146. doi:10.1016/B978-0-12-397169-2.00064-0
- 14 Niyogi SK. Shigellosis. *J Microbiol*. 2005;43: 133–143.
- 15 Holmes LC. *Shigella*. *Pediatr Rev*. 2014;35: 261–262. doi:10.1542/pir.35-6-261
- 16 Anderson M, Sansonetti PJ, Marteyn BS. *Shigella* Diversity and Changing Landscape: Insights for the Twenty-First Century. *Front Cell Infect Microbiol*. 2016;6: a014159–9. doi:10.3389/fcimb.2016.00045
- 17 Lima IFN, Havt A, Lima AAM. Update on molecular epidemiology of *Shigella* infection. *Curr Opin Gastroenterol*. 2015;31: 30–37. doi:10.1097/MOG.0000000000000136
- 18 Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, DeVinney R, et al. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. *Inflamm Bowel Dis*. 2011;17: 1971–1978. doi:10.1002/ibd.21606
- 19 Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in *Lactobacillus* in Obese Patients and Methanogens in Anorexic Patients. *Ratner AJ, editor. PLoS ONE*. 2009;4: e7125–8. doi:10.1371/journal.pone.0007125
- 20 Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, et al. Obesity-associated gut microbiota is enriched in *Lactobacillus reuteri* and depleted in *Bifidobacterium animalis* and *Methanobrevibacter smithii*. *Int J Obes (Lond)*. 2012;36: 817–825. doi:10.1038/ijo.2011.153
- 21 Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of *Lactobacillus* species on weight gain in humans and animals. *Microbial Pathogenesis*. Elsevier Ltd; 2012;53: 100–108. doi:10.1016/j.micpath.2012.05.007
- 22 Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition*. Elsevier; 2012;28: 539–543. doi:10.1016/j.nut.2011.08.013

- 23 Tonucci LB, Santos dos KMO, de Oliveira LL, Ribeiro SMR, Martino HSD. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. *Clinical Nutrition*. Elsevier Ltd; 2015;: 1–8. doi:10.1016/j.clnu.2015.11.011
- 24 Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, et al. Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR. *Am J Gastroenterology*. 2005;100: 373–382. doi:10.1111/j.1572-0241.2005.40312.x
- 25 Kale-Pradhan PB, Jassal HK, Wilhelm SM. Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. *Pharmacotherapy*. Blackwell Publishing Ltd; 2010;30: 119–126. doi:10.1592/phco.30.2.119
- 26 Lepage P, Häslér R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology*. Elsevier; 2011;141: 227–236. doi:10.1053/j.gastro.2011.04.011
- 27 Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. *FEBS Letters*. Federation of European Biochemical Societies; 2014;588: 4223–4233. doi:10.1016/j.febslet.2014.09.039
- 28 Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes. *YGAST*. Elsevier Inc; 2010;139: 1844–1854.e1. doi:10.1053/j.gastro.2010.08.049
- 29 Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature*. Nature Publishing Group; 2015;528: 262–266. doi:10.1038/nature15766
- 30 Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature*. 2012;490: 55–60. doi:10.1038/nature11450
- 31 Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreassen AS, Pedersen BK, et al. Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. Bereswill S, editor. *PLoS ONE*. 2010;5: e9085–10. doi:10.1371/journal.pone.0009085
- 32 Machiels J, Joossens M, Sabino J, De Preter V, Arijis I, Eeckhaut V, et al. A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut*. BMJ Publishing Group Ltd and British Society of Gastroenterology; 2014;63: 1275–1283. doi:10.1136/gutjnl-2013-304833
- 33 Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterology*. 2010;105: 2420–2428. doi:10.1038/ajg.2010.281
- 34 Gal-Mor O, Boyle EC, Grassl GA. Same species, different diseases: how and why typhoidal and non-typhoidal *Salmonella enterica* serovars differ. *Front Microbiol*. Frontiers; 2014;5: 391. doi:10.3389/fmicb.2014.00391
- 35 Guard-Petter J. The chicken, the egg and *Salmonella enteritidis*. *Environ Microbiol*. 2001;3: 421–430. doi:10.1128/IAI.02387-14
- 36 Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. *Lancet*. 2015;385: 1136–1145. doi:10.1016/S0140-6736(13)62708-7
- 37 Santos RL. Chapter 72. Non-typhoidal *Salmonella* Interactions with Host Cells. *Molecular Medical Microbiology, Three-Volume Set*. Elsevier Ltd; 2014. pp. 1307–1318. doi:10.1016/B978-0-12-397169-2.00072-X
- 38 Sanderson KE, Liu S-L, Le Tang, Johnston RN. Chapter 71. *Salmonella Typhi* and *Salmonella Paratyphi A*. *Molecular Medical Microbiology, Three-Volume Set*. Elsevier Ltd; 2014. pp. 1275–1306. doi:10.1016/B978-0-12-397169-2.00071-8
- 39 Santacruz A, Collado MC, García-Valdés L, Segura MT, Martín-Lagos JA, Anjos T, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. *Br J Nutr*. 2010;104: 83–92. doi:10.1017/S0007114510000176
- 40 Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut*. BMJ Publishing Group Ltd and British Society of Gastroenterology; 2014;63: 1913–1920. doi:10.1136/gutjnl-2013-306541
- 41 Jalanka-Tuovinen J, Salonen A, Nikkilä J, Immonen O, Kekkonen R, Lahti L, et al. Intestinal Microbiota in Healthy Adults: Temporal Analysis Reveals Individual and Common Core and Relation to Intestinal Symptoms. Bereswill S, editor. *PLoS ONE*. 2011;6: e23035–13. doi:10.1371/journal.pone.0023035
- 42 Zupancic ML, Cantarel BL, Liu Z, Drabek EF, Ryan KA, Cirimotich S, et al. Analysis of the Gut Microbiota in the Old Order Amish and Its Relation to the Metabolic Syndrome. Thameem F, editor. *PLoS ONE*. 2012;7: e43052–10. doi:10.1371/journal.pone.0043052
- 43 Manichanh C, Eck A, Varela E, Roca J, Clemente JC, Gonzalez A, et al. Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. *Gut*. 2014;63: 401–408. doi:10.1136/gutjnl-2012-303013

- 44 Durmaz B, Dalgalar M, Durmaz R. Prevalence of Enterotoxigenic *Bacteroides fragilis* in patients with diarrhea: A controlled study. *Anaerobe*. 2005;11: 318–321. doi:10.1016/j.anaerobe.2005.06.001
- 45 Keenan JI, Aitchison A, Purcell RV, Greenlees R, Pearson JF, Frizelle FA. Screening for enterotoxigenic *Bacteroides fragilis* in stool samples. *Anaerobe*. Elsevier Ltd; 2016;40: 50–53. doi:10.1016/j.anaerobe.2016.05.004
- 46 Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500: 541–546. doi:10.1038/nature12506
- 47 Sze MA, Schloss PD. Looking for a Signal in the Noise: Revisiting Obesity and the Microbiome. *mBio*. 2016;7: e01018–16–9. doi:10.1128/mBio.01018-16
- 48 Surawicz CM, McFarland LV. Pseudomembranous colitis: causes and cures. *Digestion*. 1999;60: 91–100.
- 49 Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for Diagnosis, Treatment, and Prevention of *Clostridium difficile* Infections. *Am J Gastroenterology*. 2013;108: 478–498. doi:10.1038/ajg.2013.4
- 50 Ofose A. *Clostridium difficile* infection: a review of current and emerging therapies. *aog*. 2016;29: 1–8. doi:10.20524/aog.2016.0006
- 51 Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. *YGASt*. 2007;133: 24–33. doi:10.1053/j.gastro.2007.04.005
- 52 Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. *Gut*. BMJ Publishing Group Ltd and British Society of Gastroenterology; 2014;63: 1737–1745. doi:10.1136/gutjnl-2013-305994
- 53 Loubinoux J, Bronowicki J-P, Pereira IAC, Mougénel J-L, Faou AE. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiology Ecology*. 2002;40: 107–112. doi:10.1111/j.1574-6941.2002.tb00942.x
- 54 Weaver GA, Krause JA, Miller TL, Wolin MJ. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. *Gut*. BMJ Group; 1986;27: 698–704.
- 55 Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. *Dig Dis Sci*. 2003;48: 86–92.
- 56 Schwartz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in Lean and Overweight Healthy Subjects. *Obesity*. Nature Publishing Group; 2009;18: 190–195. doi:10.1038/oby.2009.167
- 57 Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, et al. *Oxalobacter formigenes* may reduce the risk of calcium oxalate kidney stones. *J Am Soc Nephrol*. 2008;19: 1197–1203. doi:10.1681/ASN.2007101058
- 58 Barnett C, Nazzari L, Goldfarb DS, Blaser MJ. The Presence of *Oxalobacter formigenes* in the Microbiome of Healthy Young Adults. *Journal of Urology*. Elsevier Ltd; 2016;195: 499–506. doi:10.1016/j.juro.2015.08.070
- 59 Fite A, Macfarlane S, Furrer E, Bahrami B, Cummings JH, Steinke DT, et al. Longitudinal Analyses of Gut Mucosal Microbiotas in Ulcerative Colitis in Relation to Patient Age and Disease Severity and Duration. *J Clin Microbiol*. 2013;51: 849–856. doi:10.1128/JCM.02574-12
- 60 Kinumaki A, Sekizuka T, Hamada H, Kato K, Yamashita A, Kuroda M. Characterization of the gut microbiota of Kawasaki disease patients by metagenomic analysis. *Front Microbio*. 2015;6: 4066–11. doi:10.3389/fmicb.2015.00824
- 61 Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic *Vibrio cholerae*. *Microbiology and Molecular Biology Reviews*. 1998;62: 1301–1314.
- 62 Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. *Lancet*. 2012;379: 2466–2476. doi:10.1016/S0140-6736(12)60436-X